EGFR and non-small cell lung carcinoma: This study provides empirical evidence that skin rashes that occur after EGFR-TKI (i.e., gefitinib and erlotinib) treatment may be an efficient clinical marker for the prediction of the response of patients with NSCLC to EGFR-TKI treatment, including for the ORR and DCR.